Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need.The Company is developing MGL-3196, the first orally administered, small molecule, liver-directed hormone receptor agonist. In preclinical and Phase 1 studies, MGL-3196 has demonstrated a broad array of therapeutically beneficial effects, improving components of both metabolic syndromes, such as insulin resistance and dyslipidemia, and fatty liver disease, including lipotoxicity and inflammation.Madrigal Pharmaceuticals was acquired by Synta Pharmaceuticals on April 14, 2016